Articles from Flosonics Medical

Flosonics Medical, maker of FloPatch, the world’s first wireless, wearable Doppler ultrasound for critical care, today announced the peer-reviewed publication of the Safe and Fluid Effective Resuscitation (SaFER) protocol in SN Comprehensive Clinical Medicine. Co-authored by Flosonics co-founder and CMO Dr. Jon-Emile Kenny and Stanford University’s Dr. Carolyn Kaufman, the paper introduces a structured bedside framework for IV fluid decisions and identifies FloPatch as a practical tool to execute it, including for clinicians without advanced ultrasound training.

Flosonics Medical announced that its FloPatch wearable Doppler ultrasound device has received an Innovative Technology contract from Vizient®, the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded following review by hospital experts serving on one of Vizient’s client-led councils, who identified FloPatch’s unique potential to improve fluid management decisions and patient outcomes in sepsis care.

Sutter Health, an integrated not-for-profit healthcare system based in Northern California, and Flosonics Medical today announced an expansion of the deployment of FloPatch, the first wireless wearable Doppler ultrasound device, across multiple hospital sites to support more precise and timely intravenous (IV) fluid management. This multisite deployment includes Sutter’s Alta Bates Summit Medical Center, Summit Campus in Oakland and Sutter Santa Rosa Regional Hospital in Sonoma County. Implementations span the Emergency Department, Intensive Care Unit, Medical-Surgical Unit and Telemetry Unit. With these additions, six Sutter hospital campuses have now deployed FloPatch over the past year and include Sutter’s Eden Medical Center in Castro Valley, Sutter’s CPMC in San Francisco at CPMC Van Ness, Davies and Mission Bernal Campuses.

Flosonics Medical, the leader in wearable ultrasound for critical care, today announced that The Mount Sinai Hospital has adopted FloPatch, the first wireless Doppler ultrasound device, in its surgical and transplant intensive care units. This milestone marks the company’s first East Coast deployment, expanding its U.S. footprint and reinforcing growing demand for real-time, individualized fluid management in ICUs.

Canadian medical device innovator, Flosonics Medical, has secured $7.5 million CAD in venture debt financing from RBCx. The financing and specialized support will accelerate Flosonics Medical’s mission to improve patient outcomes through non-invasive, data-driven solutions that empower clinicians to make faster, more informed decisions at the bedside.

Flosonics Medical, a leader in wearable medical ultrasound, was selected as a Best in Class of the Digital Health Awards, presented by the Digital Health Hub Foundation in a ceremony Monday afternoon in Las Vegas at HLTH, the global healthcare conference.

Eighth paragraph of release should read: One recent study demonstrated for every 10 FloPatch assessments performed in the emergency department, roughly four patients will avoid potentially dangerous fluid overload, resulting in improved patient outcomes and significant cost savings. (instead of One recent study demonstrated that four to five patients will avoid potentially dangerous fluid overload in the emergency department for every 10 FloPatch assessments performed, resulting in improved patient outcomes and significant cost savings.)

FloPatch, a wearable ultrasound device, is in use in two critical care units at St. Michael’s Hospital.

Health System Director of Nursing to Present Processes and Advanced Techniques and Technologies Revolutionizing Sepsis Management

Flosonics Medical, a leader in wearable medical ultrasound, today announced its Series C financing, raising $20 million USD. The round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital, and iGan Partners. This new funding will support Flosonics as the company continues to innovate and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments.

Riverside University Health System is proud to announce the implementation of FloPatch by Flosonics Medical. As a pioneer in adopting new, ground-breaking medical technology, Riverside is making a significant leap forward in healthcare innovation, particularly in the life-saving area of sepsis management.

Flosonics Medical, a company dedicated to improving patient care with wireless, wearable ultrasound sensors, announced today the publication of an observational study in the Journal of Intensive Care. The results provide strong evidence for the use of FloPatch® to help prevent the over-prescription of IV fluids in adult patients with sepsis, septic shock and other hypotensive related events where IV fluids might be indicated for use.